Eli Lilly & Co. vs. Travere Therapeutics, Inc. Common Stock
Eli Lilly & Co. (LLY) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| LLY | TVTX | |
|---|---|---|
| Market Cap | $994.90 billion | $5.92 billion |
| Revenue (TTM) | $65.18 billion | — |
| Net Income (TTM) | $20.64 billion | — |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | TVTX | |
|---|---|---|
| P/E Ratio | 50.97 | — |
| Price / Book | 37.49 | — |
| Price / Sales | 15.26 | — |
LLY and TVTX split the valuation factors evenly.
Profitability
| LLY | TVTX | |
|---|---|---|
| Net Margin | 31.67% | — |
| Return on Equity | 77.78% | — |
LLY and TVTX split the profitability factors evenly.
Dividend
| LLY | TVTX | |
|---|---|---|
| Dividend Yield | 0.59% | — |
| Payout Ratio | 30.15 | — |
LLY and TVTX split the dividend factors evenly.
Risk & Sentiment
| LLY | TVTX | |
|---|---|---|
| Short Interest | 1.29% | 5.05% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, TVTX overview, TVTX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.